1	3	_	_	CD	_	_	_	_	_
2	.	_	_	.	_	_	_	_	_


1	Tailoring	_	_	VBG	_	_	_	_	_


1	Immunotherapy	_	_	NN	_	_	_	_	_
2	in	_	_	IN	_	_	_	_	_
3	Real-Life	_	_	NN	_	_	_	_	_
4	Clinical	_	_	JJ	_	_	_	_	_
5	Practice	_	_	NN	_	_	_	_	_


1	After	_	_	IN	_	_	_	_	_
2	the	_	_	DT	_	_	_	_	_
3	histology-agnostic	_	_	JJ	_	_	_	_	_
4	approval	_	_	NN	_	_	_	_	_
5	of	_	_	IN	_	_	_	_	_
6	pembrolizumab	_	_	NN	_	_	_	_	_
7	in	_	_	IN	_	_	_	_	_
8	mismatch	_	_	NN	_	_	_	_	_
9	repair	_	_	NN	_	_	_	_	_
10	(	_	_	-LRB-	_	_	_	_	_
11	MMR)-deficient	_	_	JJ	_	_	_	_	_
12	tumors	_	_	NNS	_	_	_	_	_
13	,	_	_	,	_	_	_	_	_
14	the	_	_	DT	_	_	_	_	_
15	predictive	_	_	JJ	_	_	_	_	_
16	molecular	_	_	JJ	_	_	_	_	_
17	pathology	_	_	NN	_	_	_	_	_
18	scenario	_	_	NN	_	_	_	_	_
19	in	_	_	IN	_	_	_	_	_
20	cancer	_	_	NN	_	_	_	_	_
21	immunotherapy	_	_	NN	_	_	_	_	_
22	changed	_	_	VBD	_	_	_	_	_
23	radically	_	_	RB	_	_	_	_	_
24	.	_	_	.	_	_	_	_	_


1	For	_	_	IN	_	_	_	_	_
2	the	_	_	DT	_	_	_	_	_
3	first	_	_	JJ	_	_	_	_	_
4	time	_	_	NN	_	_	_	_	_
5	in	_	_	IN	_	_	_	_	_
6	the	_	_	DT	_	_	_	_	_
7	history	_	_	NN	_	_	_	_	_
8	of	_	_	IN	_	_	_	_	_
9	medicine	_	_	NN	_	_	_	_	_
10	,	_	_	,	_	_	_	_	_
11	a	_	_	DT	_	_	_	_	_
12	drug	_	_	NN	_	_	_	_	_
13	(	_	_	-LRB-	_	_	_	_	_
14	in	_	_	IN	_	_	_	_	_
15	this	_	_	DT	_	_	_	_	_
16	case	_	_	NN	_	_	_	_	_
17	,	_	_	,	_	_	_	_	_
18	an	_	_	DT	_	_	_	_	_
19	immune-checkpoint	_	_	NN	_	_	_	_	_
20	inhibitor	_	_	NN	_	_	_	_	_
21	)	_	_	-RRB-	_	_	_	_	_
22	was	_	_	VBD	_	_	_	_	_
23	approved	_	_	VBN	_	_	_	_	_
24	based	_	_	VBN	_	_	_	_	_
25	on	_	_	IN	_	_	_	_	_
26	a	_	_	DT	_	_	_	_	_
27	specific	_	_	JJ	_	_	_	_	_
28	molecular	_	_	JJ	_	_	_	_	_
29	feature	_	_	NN	_	_	_	_	_
30	of	_	_	IN	_	_	_	_	_
31	the	_	_	DT	_	_	_	_	_
32	neoplasm	_	_	NN	_	_	_	_	_
33	,	_	_	,	_	_	_	_	_
34	irrespective	_	_	JJ	_	_	_	_	_
35	of	_	_	IN	_	_	_	_	_
36	its	_	_	PRP$	_	_	_	_	_
37	anatomical	_	_	JJ	_	_	_	_	_
38	site	_	_	NN	_	_	_	_	_
39	of	_	_	IN	_	_	_	_	_
40	origin	_	_	NN	_	_	_	_	_
41	.	_	_	.	_	_	_	_	_


1	A	_	_	DT	_	_	_	_	_
2	multitude	_	_	NN	_	_	_	_	_
3	of	_	_	IN	_	_	_	_	_
4	different	_	_	JJ	_	_	_	_	_
5	tools	_	_	NNS	_	_	_	_	_
6	has	_	_	VBZ	_	_	_	_	_
7	been	_	_	VBN	_	_	_	_	_
8	proposed	_	_	VBN	_	_	_	_	_
9	to	_	_	TO	_	_	_	_	_
10	inform	_	_	VB	_	_	_	_	_
11	immunotherapy	_	_	NN	_	_	_	_	_
12	,	_	_	,	_	_	_	_	_
13	including	_	_	VBG	_	_	_	_	_
14	morphology	_	_	NN	_	_	_	_	_
15	,	_	_	,	_	_	_	_	_
16	immunohistochemistry	_	_	NN	_	_	_	_	_
17	(	_	_	-LRB-	_	_	_	_	_
18	IHC	_	_	NN	_	_	_	_	_
19	)	_	_	-RRB-	_	_	_	_	_
20	,	_	_	,	_	_	_	_	_
21	polymerase	_	_	NN	_	_	_	_	_
22	chain	_	_	NN	_	_	_	_	_
23	reaction	_	_	NN	_	_	_	_	_
24	(	_	_	-LRB-	_	_	_	_	_
25	PCR)-based	_	_	JJ	_	_	_	_	_
26	techniques	_	_	NNS	_	_	_	_	_
27	and	_	_	CC	_	_	_	_	_
28	next-generation	_	_	JJ	_	_	_	_	_
29	technology	_	_	NN	_	_	_	_	_
30	assays	_	_	NNS	_	_	_	_	_
31	,	_	_	,	_	_	_	_	_
32	such	_	_	JJ	_	_	_	_	_
33	as	_	_	IN	_	_	_	_	_
34	next-generation	_	_	JJ	_	_	_	_	_
35	sequencing	_	_	NN	_	_	_	_	_
36	(	_	_	-LRB-	_	_	_	_	_
37	NGS	_	_	NN	_	_	_	_	_
38	)	_	_	-RRB-	_	_	_	_	_
39	or	_	_	CC	_	_	_	_	_
40	multiplex	_	_	NN	_	_	_	_	_
41	barcode	_	_	NN	_	_	_	_	_
42	technology	_	_	NN	_	_	_	_	_
43	(	_	_	-LRB-	_	_	_	_	_
44	e.	_	_	FW	_	_	_	_	_
45	g.	_	_	FW	_	_	_	_	_
46	,	_	_	,	_	_	_	_	_
47	NanoString	_	_	NNP	_	_	_	_	_
48	)	_	_	-RRB-	_	_	_	_	_
49	.	_	_	.	_	_	_	_	_


1	However	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	not	_	_	RB	_	_	_	_	_
4	all	_	_	PDT	_	_	_	_	_
5	the	_	_	DT	_	_	_	_	_
6	available	_	_	JJ	_	_	_	_	_
7	tools	_	_	NNS	_	_	_	_	_
8	are	_	_	VBP	_	_	_	_	_
9	validated	_	_	VBN	_	_	_	_	_
10	for	_	_	IN	_	_	_	_	_
11	patients	_	_	NNS	_	_	_	_	_
12	’	_	_	POS	_	_	_	_	_
13	selection	_	_	NN	_	_	_	_	_
14	in	_	_	IN	_	_	_	_	_
15	clinical	_	_	JJ	_	_	_	_	_
16	practice	_	_	NN	_	_	_	_	_
17	,	_	_	,	_	_	_	_	_
18	as	_	_	IN	_	_	_	_	_
19	shown	_	_	VBN	_	_	_	_	_
20	in	_	_	IN	_	_	_	_	_


1	Figure	_	_	NN	_	_	_	_	_
2	1	_	_	CD	_	_	_	_	_


1	.	_	_	.	_	_	_	_	_


1	Among	_	_	IN	_	_	_	_	_
2	new	_	_	JJ	_	_	_	_	_
3	biomarkers	_	_	NNS	_	_	_	_	_
4	to	_	_	TO	_	_	_	_	_
5	select	_	_	VB	_	_	_	_	_
6	patients	_	_	NNS	_	_	_	_	_
7	for	_	_	IN	_	_	_	_	_
8	immunotherapy	_	_	NN	_	_	_	_	_
9	,	_	_	,	_	_	_	_	_
10	the	_	_	DT	_	_	_	_	_
11	tumor	_	_	NN	_	_	_	_	_
12	mutational	_	_	JJ	_	_	_	_	_
13	burden	_	_	NN	_	_	_	_	_
14	(	_	_	-LRB-	_	_	_	_	_
15	TMB	_	_	NN	_	_	_	_	_
16	)	_	_	-RRB-	_	_	_	_	_
17	has	_	_	VBZ	_	_	_	_	_
18	been	_	_	VBN	_	_	_	_	_
19	shown	_	_	VBN	_	_	_	_	_
20	a	_	_	DT	_	_	_	_	_
21	strong	_	_	JJ	_	_	_	_	_
22	correlation	_	_	NN	_	_	_	_	_
23	with	_	_	IN	_	_	_	_	_
24	the	_	_	DT	_	_	_	_	_
25	response	_	_	NN	_	_	_	_	_
26	to	_	_	TO	_	_	_	_	_
27	some	_	_	DT	_	_	_	_	_
28	compounds	_	_	NNS	_	_	_	_	_
29	.	_	_	.	_	_	_	_	_


1	TMB	_	_	NNP	_	_	_	_	_
2	is	_	_	VBZ	_	_	_	_	_
3	defined	_	_	VBN	_	_	_	_	_
4	by	_	_	IN	_	_	_	_	_
5	the	_	_	DT	_	_	_	_	_
6	total	_	_	JJ	_	_	_	_	_
7	number	_	_	NN	_	_	_	_	_
8	of	_	_	IN	_	_	_	_	_
9	somatic	_	_	JJ	_	_	_	_	_
10	nonsynonymous	_	_	JJ	_	_	_	_	_
11	mutations	_	_	NNS	_	_	_	_	_
12	per	_	_	IN	_	_	_	_	_
13	coding	_	_	VBG	_	_	_	_	_
14	area	_	_	NN	_	_	_	_	_
15	of	_	_	IN	_	_	_	_	_
16	the	_	_	DT	_	_	_	_	_
17	tumor	_	_	NN	_	_	_	_	_
18	DNA	_	_	NN	_	_	_	_	_
19	.	_	_	.	_	_	_	_	_


1	It	_	_	PRP	_	_	_	_	_
2	has	_	_	VBZ	_	_	_	_	_
3	been	_	_	VBN	_	_	_	_	_
4	hypothesized	_	_	VBN	_	_	_	_	_
5	that	_	_	IN	_	_	_	_	_
6	tumors	_	_	NNS	_	_	_	_	_
7	with	_	_	IN	_	_	_	_	_
8	a	_	_	DT	_	_	_	_	_
9	higher	_	_	JJR	_	_	_	_	_
10	TMB	_	_	NN	_	_	_	_	_
11	are	_	_	VBP	_	_	_	_	_
12	more	_	_	RBR	_	_	_	_	_
13	likely	_	_	JJ	_	_	_	_	_
14	to	_	_	TO	_	_	_	_	_
15	express	_	_	VB	_	_	_	_	_
16	neoantigens	_	_	NNS	_	_	_	_	_
17	and	_	_	CC	_	_	_	_	_
18	to	_	_	TO	_	_	_	_	_
19	induce	_	_	VB	_	_	_	_	_
20	a	_	_	DT	_	_	_	_	_
21	more	_	_	RBR	_	_	_	_	_
22	robust	_	_	JJ	_	_	_	_	_
23	immune	_	_	JJ	_	_	_	_	_
24	response	_	_	NN	_	_	_	_	_
25	in	_	_	IN	_	_	_	_	_
26	the	_	_	DT	_	_	_	_	_
27	presence	_	_	NN	_	_	_	_	_
28	of	_	_	IN	_	_	_	_	_
29	immune	_	_	JJ	_	_	_	_	_
30	checkpoint	_	_	NN	_	_	_	_	_
31	inhibitors	_	_	NNS	_	_	_	_	_
32	.	_	_	.	_	_	_	_	_


1	Regrettably	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	the	_	_	DT	_	_	_	_	_
4	TMB	_	_	NN	_	_	_	_	_
5	analysis	_	_	NN	_	_	_	_	_
6	is	_	_	VBZ	_	_	_	_	_
7	considered	_	_	VBN	_	_	_	_	_
8	expensive	_	_	JJ	_	_	_	_	_
9	,	_	_	,	_	_	_	_	_
10	time-consuming	_	_	JJ	_	_	_	_	_
11	,	_	_	,	_	_	_	_	_
12	and	_	_	CC	_	_	_	_	_
13	deceptive	_	_	JJ	_	_	_	_	_
14	if	_	_	IN	_	_	_	_	_
15	the	_	_	DT	_	_	_	_	_
16	analyses	_	_	NNS	_	_	_	_	_
17	are	_	_	VBP	_	_	_	_	_
18	carried	_	_	VBN	_	_	_	_	_
19	out	_	_	RP	_	_	_	_	_
20	with	_	_	IN	_	_	_	_	_
21	an	_	_	DT	_	_	_	_	_
22	unsuitable	_	_	JJ	_	_	_	_	_
23	NGS	_	_	NNP	_	_	_	_	_
24	panel	_	_	NN	_	_	_	_	_
25	.	_	_	.	_	_	_	_	_


1	Another	_	_	DT	_	_	_	_	_
2	important	_	_	JJ	_	_	_	_	_
3	facet	_	_	NN	_	_	_	_	_
4	in	_	_	IN	_	_	_	_	_
5	TMB	_	_	NN	_	_	_	_	_
6	analysis	_	_	NN	_	_	_	_	_
7	is	_	_	VBZ	_	_	_	_	_
8	represented	_	_	VBN	_	_	_	_	_
9	by	_	_	IN	_	_	_	_	_
10	the	_	_	DT	_	_	_	_	_
11	lack	_	_	NN	_	_	_	_	_
12	of	_	_	IN	_	_	_	_	_
13	widely	_	_	RB	_	_	_	_	_
14	adopted	_	_	VBN	_	_	_	_	_
15	guidelines	_	_	NNS	_	_	_	_	_
16	and	_	_	CC	_	_	_	_	_
17	recommendations	_	_	NNS	_	_	_	_	_
18	for	_	_	IN	_	_	_	_	_
19	its	_	_	PRP$	_	_	_	_	_
20	assessment	_	_	NN	_	_	_	_	_
21	and	_	_	CC	_	_	_	_	_
22	reporting	_	_	NN	_	_	_	_	_
23	.	_	_	.	_	_	_	_	_


1	Initially	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	TMB	_	_	NNP	_	_	_	_	_
4	was	_	_	VBD	_	_	_	_	_
5	determined	_	_	VBN	_	_	_	_	_
6	using	_	_	VBG	_	_	_	_	_
7	wide	_	_	JJ	_	_	_	_	_
8	approaches	_	_	NNS	_	_	_	_	_
9	(	_	_	-LRB-	_	_	_	_	_
10	e.	_	_	FW	_	_	_	_	_
11	g.	_	_	FW	_	_	_	_	_
12	,	_	_	,	_	_	_	_	_
13	whole	_	_	JJ	_	_	_	_	_
14	exome	_	_	NN	_	_	_	_	_
15	sequencing	_	_	NN	_	_	_	_	_
16	)	_	_	-RRB-	_	_	_	_	_
17	,	_	_	,	_	_	_	_	_
18	but	_	_	CC	_	_	_	_	_
19	more	_	_	RBR	_	_	_	_	_
20	focused	_	_	VBN	_	_	_	_	_
21	gene	_	_	NN	_	_	_	_	_
22	panels	_	_	NNS	_	_	_	_	_
23	are	_	_	VBP	_	_	_	_	_
24	currently	_	_	RB	_	_	_	_	_
25	being	_	_	VBG	_	_	_	_	_
26	explored	_	_	VBN	_	_	_	_	_
27	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	addition	_	_	NN	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	there	_	_	EX	_	_	_	_	_
5	are	_	_	VBP	_	_	_	_	_
6	several	_	_	JJ	_	_	_	_	_
7	indications	_	_	NNS	_	_	_	_	_
8	that	_	_	IN	_	_	_	_	_
9	TMB	_	_	NNP	_	_	_	_	_
10	is	_	_	VBZ	_	_	_	_	_
11	not	_	_	RB	_	_	_	_	_
12	a	_	_	DT	_	_	_	_	_
13	universal	_	_	JJ	_	_	_	_	_
14	biomarker	_	_	NN	_	_	_	_	_
15	,	_	_	,	_	_	_	_	_
16	as	_	_	IN	_	_	_	_	_
17	its	_	_	PRP$	_	_	_	_	_
18	value	_	_	NN	_	_	_	_	_
19	varies	_	_	VBZ	_	_	_	_	_
20	not	_	_	RB	_	_	_	_	_
21	only	_	_	RB	_	_	_	_	_
22	across	_	_	IN	_	_	_	_	_
23	tumor	_	_	NN	_	_	_	_	_
24	types	_	_	NNS	_	_	_	_	_
25	but	_	_	CC	_	_	_	_	_
26	also	_	_	RB	_	_	_	_	_
27	across	_	_	IN	_	_	_	_	_
28	different	_	_	JJ	_	_	_	_	_
29	genomic	_	_	JJ	_	_	_	_	_
30	regions	_	_	NNS	_	_	_	_	_
31	and	_	_	CC	_	_	_	_	_
32	during	_	_	IN	_	_	_	_	_
33	the	_	_	DT	_	_	_	_	_
34	time	_	_	NN	_	_	_	_	_
35	.	_	_	.	_	_	_	_	_


1	This	_	_	DT	_	_	_	_	_
2	notion	_	_	NN	_	_	_	_	_
3	highlights	_	_	VBZ	_	_	_	_	_
4	the	_	_	DT	_	_	_	_	_
5	need	_	_	NN	_	_	_	_	_
6	for	_	_	IN	_	_	_	_	_
7	disease-specific	_	_	JJ	_	_	_	_	_
8	TMB	_	_	NN	_	_	_	_	_
9	panels	_	_	NNS	_	_	_	_	_
10	and	_	_	CC	_	_	_	_	_
11	thresholds	_	_	NNS	_	_	_	_	_
12	.	_	_	.	_	_	_	_	_


1	Likewise	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	the	_	_	DT	_	_	_	_	_
4	analysis	_	_	NN	_	_	_	_	_
5	of	_	_	IN	_	_	_	_	_
6	the	_	_	DT	_	_	_	_	_
7	MMR	_	_	NNP	_	_	_	_	_
8	status	_	_	NN	_	_	_	_	_
9	is	_	_	VBZ	_	_	_	_	_
10	troubled	_	_	VBN	_	_	_	_	_
11	by	_	_	IN	_	_	_	_	_
12	the	_	_	DT	_	_	_	_	_
13	vastity	_	_	NN	_	_	_	_	_
14	of	_	_	IN	_	_	_	_	_
15	the	_	_	DT	_	_	_	_	_
16	existing	_	_	VBG	_	_	_	_	_
17	diagnostic	_	_	JJ	_	_	_	_	_
18	methods	_	_	NNS	_	_	_	_	_
19	in	_	_	IN	_	_	_	_	_
20	the	_	_	DT	_	_	_	_	_
21	substantial	_	_	JJ	_	_	_	_	_
22	absence	_	_	NN	_	_	_	_	_
23	of	_	_	IN	_	_	_	_	_
24	companion	_	_	NN	_	_	_	_	_
25	diagnostic	_	_	JJ	_	_	_	_	_
26	(	_	_	-LRB-	_	_	_	_	_
27	CD	_	_	NN	_	_	_	_	_
28	)	_	_	-RRB-	_	_	_	_	_
29	tests	_	_	NNS	_	_	_	_	_
30	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	general	_	_	JJ	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	MMR	_	_	NNP	_	_	_	_	_
5	IHC	_	_	NNP	_	_	_	_	_
6	is	_	_	VBZ	_	_	_	_	_
7	mirrored	_	_	VBN	_	_	_	_	_
8	by	_	_	IN	_	_	_	_	_
9	microsatellite	_	_	JJ	_	_	_	_	_
10	instability	_	_	NN	_	_	_	_	_
11	(	_	_	-LRB-	_	_	_	_	_
12	MSI	_	_	NN	_	_	_	_	_
13	)	_	_	-RRB-	_	_	_	_	_
14	in	_	_	IN	_	_	_	_	_
15	endometrial	_	_	JJ	_	_	_	_	_
16	and	_	_	CC	_	_	_	_	_
17	colorectal	_	_	JJ	_	_	_	_	_
18	cancers	_	_	NNS	_	_	_	_	_
19	.	_	_	.	_	_	_	_	_


1	However	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	not	_	_	RB	_	_	_	_	_
4	all	_	_	DT	_	_	_	_	_
5	MMR-deficient	_	_	JJ	_	_	_	_	_
6	tumors	_	_	NNS	_	_	_	_	_
7	show	_	_	VBP	_	_	_	_	_
8	MSI	_	_	NNP	_	_	_	_	_
9	(	_	_	-LRB-	_	_	_	_	_
10	e.	_	_	FW	_	_	_	_	_
11	g.	_	_	FW	_	_	_	_	_
12	,	_	_	,	_	_	_	_	_
13	breast	_	_	NN	_	_	_	_	_
14	cancers	_	_	NNS	_	_	_	_	_
15	)	_	_	-RRB-	_	_	_	_	_
16	,	_	_	,	_	_	_	_	_
17	questioning	_	_	VBG	_	_	_	_	_
18	the	_	_	DT	_	_	_	_	_
19	interchangeability	_	_	NN	_	_	_	_	_
20	of	_	_	IN	_	_	_	_	_
21	these	_	_	DT	_	_	_	_	_
22	analyses	_	_	NNS	_	_	_	_	_
23	as	_	_	IN	_	_	_	_	_
24	pan-cancer	_	_	NN	_	_	_	_	_
25	predictive	_	_	JJ	_	_	_	_	_
26	tests	_	_	NNS	_	_	_	_	_
27	.	_	_	.	_	_	_	_	_


1	Hence	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	MMR/MSI	_	_	NNP	_	_	_	_	_
4	assays	_	_	NNS	_	_	_	_	_
5	have	_	_	VBP	_	_	_	_	_
6	been	_	_	VBN	_	_	_	_	_
7	originally	_	_	RB	_	_	_	_	_
8	developed	_	_	VBN	_	_	_	_	_
9	by	_	_	IN	_	_	_	_	_
10	geneticists	_	_	NNS	_	_	_	_	_
11	to	_	_	TO	_	_	_	_	_
12	identify	_	_	VB	_	_	_	_	_
13	Lynch	_	_	NNP	_	_	_	_	_
14	syndrome	_	_	NN	_	_	_	_	_
15	families	_	_	NNS	_	_	_	_	_
16	and	_	_	CC	_	_	_	_	_
17	not	_	_	RB	_	_	_	_	_
18	for	_	_	IN	_	_	_	_	_
19	choosing	_	_	VBG	_	_	_	_	_
20	the	_	_	DT	_	_	_	_	_
21	optimal	_	_	JJ	_	_	_	_	_
22	drug	_	_	NN	_	_	_	_	_
23	to	_	_	TO	_	_	_	_	_
24	treat	_	_	VB	_	_	_	_	_
25	acquired	_	_	VBN	_	_	_	_	_
26	tumors	_	_	NNS	_	_	_	_	_
27	.	_	_	.	_	_	_	_	_


1	Given	_	_	VBN	_	_	_	_	_
2	the	_	_	DT	_	_	_	_	_
3	wide	_	_	JJ	_	_	_	_	_
4	heterogeneity	_	_	NN	_	_	_	_	_
5	in	_	_	IN	_	_	_	_	_
6	the	_	_	DT	_	_	_	_	_
7	repertoire	_	_	NN	_	_	_	_	_
8	of	_	_	IN	_	_	_	_	_
9	molecular	_	_	JJ	_	_	_	_	_
10	alterations	_	_	NNS	_	_	_	_	_
11	in	_	_	IN	_	_	_	_	_
12	immune-related	_	_	JJ	_	_	_	_	_
13	genes	_	_	NNS	_	_	_	_	_
14	across	_	_	IN	_	_	_	_	_
15	different	_	_	JJ	_	_	_	_	_
16	tumor	_	_	NN	_	_	_	_	_
17	types	_	_	NNS	_	_	_	_	_
18	(	_	_	-LRB-	_	_	_	_	_


1	Figure	_	_	NN	_	_	_	_	_
2	2	_	_	CD	_	_	_	_	_


1	)	_	_	-RRB-	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	novel	_	_	JJ	_	_	_	_	_
4	,	_	_	,	_	_	_	_	_
5	efficient	_	_	JJ	_	_	_	_	_
6	,	_	_	,	_	_	_	_	_
7	reproducible	_	_	JJ	_	_	_	_	_
8	,	_	_	,	_	_	_	_	_
9	and	_	_	CC	_	_	_	_	_
10	reliable	_	_	JJ	_	_	_	_	_
11	techniques	_	_	NNS	_	_	_	_	_
12	coupled	_	_	VBN	_	_	_	_	_
13	with	_	_	IN	_	_	_	_	_
14	tumor-specific	_	_	JJ	_	_	_	_	_
15	methods	_	_	NNS	_	_	_	_	_
16	and	_	_	CC	_	_	_	_	_
17	guidelines	_	_	NNS	_	_	_	_	_
18	are	_	_	VBP	_	_	_	_	_
19	needed	_	_	VBN	_	_	_	_	_
20	.	_	_	.	_	_	_	_	_


1	Another	_	_	DT	_	_	_	_	_
2	important	_	_	JJ	_	_	_	_	_
3	issue	_	_	NN	_	_	_	_	_
4	related	_	_	VBN	_	_	_	_	_
5	to	_	_	TO	_	_	_	_	_
6	the	_	_	DT	_	_	_	_	_
7	patient	_	_	NN	_	_	_	_	_
8	’s	_	_	POS	_	_	_	_	_
9	selection	_	_	NN	_	_	_	_	_
10	for	_	_	IN	_	_	_	_	_
11	immunotherapy	_	_	NN	_	_	_	_	_
12	is	_	_	VBZ	_	_	_	_	_
13	represented	_	_	VBN	_	_	_	_	_
14	by	_	_	IN	_	_	_	_	_
15	the	_	_	DT	_	_	_	_	_
16	PD-L1	_	_	NNP	_	_	_	_	_
17	analysis	_	_	NN	_	_	_	_	_
18	by	_	_	IN	_	_	_	_	_
19	IHC	_	_	NNP	_	_	_	_	_
20	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	this	_	_	DT	_	_	_	_	_
3	respect	_	_	NN	_	_	_	_	_
4	,	_	_	,	_	_	_	_	_
5	important	_	_	JJ	_	_	_	_	_
6	harmonization	_	_	NN	_	_	_	_	_
7	efforts	_	_	NNS	_	_	_	_	_
8	have	_	_	VBP	_	_	_	_	_
9	been	_	_	VBN	_	_	_	_	_
10	made	_	_	VBN	_	_	_	_	_
11	to	_	_	TO	_	_	_	_	_
12	standardize	_	_	VB	_	_	_	_	_
13	both	_	_	CC	_	_	_	_	_
14	the	_	_	DT	_	_	_	_	_
15	preanalytical	_	_	JJ	_	_	_	_	_
16	and	_	_	CC	_	_	_	_	_
17	interpretative	_	_	JJ	_	_	_	_	_
18	phases	_	_	NNS	_	_	_	_	_
19	of	_	_	IN	_	_	_	_	_
20	PD-L1	_	_	NN	_	_	_	_	_
21	testing	_	_	NN	_	_	_	_	_
22	,	_	_	,	_	_	_	_	_
23	at	_	_	IN	_	_	_	_	_
24	least	_	_	JJS	_	_	_	_	_
25	in	_	_	IN	_	_	_	_	_
26	non-small	_	_	JJ	_	_	_	_	_
27	cell	_	_	NN	_	_	_	_	_
28	lung	_	_	NN	_	_	_	_	_
29	cancer	_	_	NN	_	_	_	_	_
30	(	_	_	-LRB-	_	_	_	_	_
31	NSCLC	_	_	NNP	_	_	_	_	_
32	)	_	_	-RRB-	_	_	_	_	_
33	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	reproducibility	_	_	NN	_	_	_	_	_
3	of	_	_	IN	_	_	_	_	_
4	PD-L1	_	_	NN	_	_	_	_	_
5	testing	_	_	NN	_	_	_	_	_
6	in	_	_	IN	_	_	_	_	_
7	real-life	_	_	JJ	_	_	_	_	_
8	clinical	_	_	JJ	_	_	_	_	_
9	practice	_	_	NN	_	_	_	_	_
10	evaluated	_	_	VBD	_	_	_	_	_
11	both	_	_	DT	_	_	_	_	_
12	for	_	_	IN	_	_	_	_	_
13	“	_	_	``	_	_	_	_	_
14	closed	_	_	VBN	_	_	_	_	_
15	”	_	_	''	_	_	_	_	_
16	and	_	_	CC	_	_	_	_	_
17	“	_	_	``	_	_	_	_	_
18	open	_	_	JJ	_	_	_	_	_
19	”	_	_	''	_	_	_	_	_
20	platforms	_	_	NNS	_	_	_	_	_
21	,	_	_	,	_	_	_	_	_
22	showed	_	_	VBD	_	_	_	_	_
23	overlapping	_	_	VBG	_	_	_	_	_
24	results	_	_	NNS	_	_	_	_	_
25	,	_	_	,	_	_	_	_	_
26	particularly	_	_	RB	_	_	_	_	_
27	when	_	_	WRB	_	_	_	_	_
28	the	_	_	DT	_	_	_	_	_
29	22C3	_	_	CD	_	_	_	_	_
30	antibody	_	_	NN	_	_	_	_	_
31	clone	_	_	NN	_	_	_	_	_
32	was	_	_	VBD	_	_	_	_	_
33	used	_	_	VBN	_	_	_	_	_
34	.	_	_	.	_	_	_	_	_


1	On	_	_	IN	_	_	_	_	_
2	the	_	_	DT	_	_	_	_	_
3	other	_	_	JJ	_	_	_	_	_
4	hand	_	_	NN	_	_	_	_	_
5	,	_	_	,	_	_	_	_	_
6	there	_	_	EX	_	_	_	_	_
7	are	_	_	VBP	_	_	_	_	_
8	several	_	_	JJ	_	_	_	_	_
9	clues	_	_	NNS	_	_	_	_	_
10	to	_	_	TO	_	_	_	_	_
11	advise	_	_	VB	_	_	_	_	_
12	that	_	_	IN	_	_	_	_	_
13	the	_	_	DT	_	_	_	_	_
14	same	_	_	JJ	_	_	_	_	_
15	interpretation	_	_	NN	_	_	_	_	_
16	guidelines	_	_	NNS	_	_	_	_	_
17	should	_	_	MD	_	_	_	_	_
18	not	_	_	RB	_	_	_	_	_
19	be	_	_	VB	_	_	_	_	_
20	translated	_	_	VBN	_	_	_	_	_
21	across	_	_	IN	_	_	_	_	_
22	different	_	_	JJ	_	_	_	_	_
23	tumor	_	_	NN	_	_	_	_	_
24	types	_	_	NNS	_	_	_	_	_
25	.	_	_	.	_	_	_	_	_


1	For	_	_	IN	_	_	_	_	_
2	example	_	_	NN	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	the	_	_	DT	_	_	_	_	_
5	tumor	_	_	NN	_	_	_	_	_
6	proportion	_	_	NN	_	_	_	_	_
7	score	_	_	NN	_	_	_	_	_
8	(	_	_	-LRB-	_	_	_	_	_
9	TPS	_	_	NN	_	_	_	_	_
10	)	_	_	-RRB-	_	_	_	_	_
11	works	_	_	VBZ	_	_	_	_	_
12	perfectly	_	_	RB	_	_	_	_	_
13	for	_	_	IN	_	_	_	_	_
14	lung	_	_	NN	_	_	_	_	_
15	cancer	_	_	NN	_	_	_	_	_
16	but	_	_	CC	_	_	_	_	_
17	not	_	_	RB	_	_	_	_	_
18	for	_	_	IN	_	_	_	_	_
19	head	_	_	NN	_	_	_	_	_
20	and	_	_	CC	_	_	_	_	_
21	neck	_	_	NN	_	_	_	_	_
22	cancer	_	_	NN	_	_	_	_	_
23	,	_	_	,	_	_	_	_	_
24	where	_	_	WRB	_	_	_	_	_
25	the	_	_	DT	_	_	_	_	_
26	combined	_	_	VBN	_	_	_	_	_
27	positive	_	_	JJ	_	_	_	_	_
28	score	_	_	NN	_	_	_	_	_
29	(	_	_	-LRB-	_	_	_	_	_
30	CPS	_	_	NN	_	_	_	_	_
31	)	_	_	-RRB-	_	_	_	_	_
32	is	_	_	VBZ	_	_	_	_	_
33	more	_	_	RBR	_	_	_	_	_
34	reliable	_	_	JJ	_	_	_	_	_
35	.	_	_	.	_	_	_	_	_


1	These	_	_	DT	_	_	_	_	_
2	two	_	_	CD	_	_	_	_	_
3	scoring	_	_	NN	_	_	_	_	_
4	systems	_	_	NNS	_	_	_	_	_
5	are	_	_	VBP	_	_	_	_	_
6	rather	_	_	RB	_	_	_	_	_
7	different	_	_	JJ	_	_	_	_	_
8	,	_	_	,	_	_	_	_	_
9	given	_	_	VBN	_	_	_	_	_
10	that	_	_	IN	_	_	_	_	_
11	the	_	_	DT	_	_	_	_	_
12	former	_	_	JJ	_	_	_	_	_
13	considers	_	_	VBZ	_	_	_	_	_
14	only	_	_	RB	_	_	_	_	_
15	the	_	_	DT	_	_	_	_	_
16	percentage	_	_	NN	_	_	_	_	_
17	of	_	_	IN	_	_	_	_	_
18	PD-L1-positive	_	_	JJ	_	_	_	_	_
19	neoplastic	_	_	JJ	_	_	_	_	_
20	cells	_	_	NNS	_	_	_	_	_
21	,	_	_	,	_	_	_	_	_
22	while	_	_	IN	_	_	_	_	_
23	the	_	_	DT	_	_	_	_	_
24	latter	_	_	NN	_	_	_	_	_
25	combines	_	_	VBZ	_	_	_	_	_
26	all	_	_	DT	_	_	_	_	_
27	PD-L1-positive	_	_	JJ	_	_	_	_	_
28	cells	_	_	NNS	_	_	_	_	_
29	(	_	_	-LRB-	_	_	_	_	_
30	i.	_	_	FW	_	_	_	_	_
31	e.	_	_	FW	_	_	_	_	_
32	,	_	_	,	_	_	_	_	_
33	tumor	_	_	NN	_	_	_	_	_
34	cells	_	_	NNS	_	_	_	_	_
35	,	_	_	,	_	_	_	_	_
36	lymphocytes	_	_	NNS	_	_	_	_	_
37	,	_	_	,	_	_	_	_	_
38	and	_	_	CC	_	_	_	_	_
39	macrophages	_	_	NNS	_	_	_	_	_
40	)	_	_	-RRB-	_	_	_	_	_
41	into	_	_	IN	_	_	_	_	_
42	the	_	_	DT	_	_	_	_	_
43	following	_	_	VBG	_	_	_	_	_
44	formula	_	_	NN	_	_	_	_	_
45	.	_	_	.	_	_	_	_	_


1	Although	_	_	IN	_	_	_	_	_
2	the	_	_	DT	_	_	_	_	_
3	CPS	_	_	NNP	_	_	_	_	_
4	can	_	_	MD	_	_	_	_	_
5	theoretically	_	_	RB	_	_	_	_	_
6	exceed	_	_	VB	_	_	_	_	_
7	the	_	_	DT	_	_	_	_	_
8	value	_	_	NN	_	_	_	_	_
9	of	_	_	IN	_	_	_	_	_
10	100	_	_	CD	_	_	_	_	_
11	,	_	_	,	_	_	_	_	_
12	the	_	_	DT	_	_	_	_	_
13	maximum	_	_	JJ	_	_	_	_	_
14	score	_	_	NN	_	_	_	_	_
15	is	_	_	VBZ	_	_	_	_	_
16	defined	_	_	VBN	_	_	_	_	_
17	as	_	_	IN	_	_	_	_	_
18	100	_	_	CD	_	_	_	_	_
19	.	_	_	.	_	_	_	_	_


1	Fascinating	_	_	JJ	_	_	_	_	_
2	perspectives	_	_	NNS	_	_	_	_	_
3	are	_	_	VBP	_	_	_	_	_
4	being	_	_	VBG	_	_	_	_	_
5	provided	_	_	VBN	_	_	_	_	_
6	by	_	_	IN	_	_	_	_	_
7	experimental	_	_	JJ	_	_	_	_	_
8	models	_	_	NNS	_	_	_	_	_
9	addressing	_	_	VBG	_	_	_	_	_
10	the	_	_	DT	_	_	_	_	_
11	plasticity	_	_	NN	_	_	_	_	_
12	of	_	_	IN	_	_	_	_	_
13	the	_	_	DT	_	_	_	_	_
14	cellular	_	_	JJ	_	_	_	_	_
15	inflammatory	_	_	JJ	_	_	_	_	_
16	response	_	_	NN	_	_	_	_	_
17	of	_	_	IN	_	_	_	_	_
18	the	_	_	DT	_	_	_	_	_
19	host	_	_	NN	_	_	_	_	_
20	.	_	_	.	_	_	_	_	_


1	There	_	_	EX	_	_	_	_	_
2	are	_	_	VBP	_	_	_	_	_
3	several	_	_	JJ	_	_	_	_	_
4	lines	_	_	NNS	_	_	_	_	_
5	of	_	_	IN	_	_	_	_	_
6	evidence	_	_	NN	_	_	_	_	_
7	to	_	_	TO	_	_	_	_	_
8	suggest	_	_	VB	_	_	_	_	_
9	that	_	_	IN	_	_	_	_	_
10	the	_	_	DT	_	_	_	_	_
11	myeloid-derived	_	_	JJ	_	_	_	_	_
12	cell	_	_	NN	_	_	_	_	_
13	function	_	_	NN	_	_	_	_	_
14	is	_	_	VBZ	_	_	_	_	_
15	a	_	_	DT	_	_	_	_	_
16	finely	_	_	RB	_	_	_	_	_
17	tuned	_	_	VBN	_	_	_	_	_
18	mechanism	_	_	NN	_	_	_	_	_
19	to	_	_	TO	_	_	_	_	_
20	control	_	_	VB	_	_	_	_	_
21	tumor	_	_	NN	_	_	_	_	_
22	growth	_	_	NN	_	_	_	_	_
23	.	_	_	.	_	_	_	_	_


1	Specifically	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	both	_	_	DT	_	_	_	_	_
4	in	_	_	IN	_	_	_	_	_
5	local	_	_	JJ	_	_	_	_	_
6	and	_	_	CC	_	_	_	_	_
7	hematopoietic	_	_	JJ	_	_	_	_	_
8	niches	_	_	NNS	_	_	_	_	_
9	,	_	_	,	_	_	_	_	_
10	its	_	_	PRP$	_	_	_	_	_
11	crosstalk	_	_	NN	_	_	_	_	_
12	with	_	_	IN	_	_	_	_	_
13	the	_	_	DT	_	_	_	_	_
14	tumor	_	_	NN	_	_	_	_	_
15	cells	_	_	NNS	_	_	_	_	_
16	as	_	_	RB	_	_	_	_	_
17	well	_	_	RB	_	_	_	_	_
18	as	_	_	IN	_	_	_	_	_
19	with	_	_	IN	_	_	_	_	_
20	exogenous	_	_	JJ	_	_	_	_	_
21	stimuli	_	_	NNS	_	_	_	_	_
22	,	_	_	,	_	_	_	_	_
23	is	_	_	VBZ	_	_	_	_	_
24	based	_	_	VBN	_	_	_	_	_
25	on	_	_	IN	_	_	_	_	_
26	the	_	_	DT	_	_	_	_	_
27	microbiota	_	_	NN	_	_	_	_	_
28	repertoire	_	_	NN	_	_	_	_	_
29	.	_	_	.	_	_	_	_	_

